Clinical assessment of secondary AA amyloidosis associated with rheumatoid arthritis

Clinical assessment of secondary AA amyloidosis associated with rheumatoid arthritis - Clinical assessment of secondary AA amyloidosis associated with rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003294

Enrollment

Registered

2010-03-05

Start date

2003-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis, AA amyloidosis

Interventions

Administration of immunosuppressive drugs for inflammatory response of rheumatoid arthritis as long as in the absence of adverse effect. Administration of anti-hypertensive drugs for hypertension as l

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The enrolled patients have history of rheumatoid arthritis and has been diagnosed as systemic secondary AA amyloidosis by biopsy specimen.

Exclusion criteria

Exclusion criteria: These patients were excluded who has diabetic nephropathy or other proteinuric disease, and who does not have history of rheumatoid arthritis.

Design outcomes

Primary

Measure	Time frame
Improvement of disaese activity of rheumatoid arthritis, organ dysfunctions and life prognosis.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026